The cure for diabetes is a life free from daily insulin injections. Based on that criterion, ten out of 12 people (83%) in a new clinical trial were cured of their diabetes one year after ...

Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer ...

A recently-approved treatment could take a BiTE out of small cell lung cancer by using a person's own body to fight back.

Regulatory submission is based on positive results from the ongoing Phase I/II SOHO-01 trial in patients with advanced HER2-mutant non-small cell lung cancer (NSCLC). Investigational agent ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

Crown Castle’s small cells solutions business is a provider of digital infrastructure, specializing in the deployment of small cell networks that enhance essential wireless connectivity.

Newer treatments target pathways like Delta-like ligand 3, poly-ADP-ribose polymerase, and histone deacetylase to address small cell lung cancer's aggressive nature and resistance to conventional ...

Learn why small cell lung cancer is difficult to treat and why the outlook is less favorable.

A team of doctors and researchers have identified a new, rare type of small cell lung cancer that primarily affects younger people who have never smoked.

Imdelltra has offered a new treatment option for patients with small cell lung cancer that “is not like anything we’ve ever seen before,” an expert said.

In patients with advanced non–small cell lung cancer without actionable genomic alterations, whose tumors progress during or after first-line chemoimmunotherapy, second-line monotherapy with docetaxel ...

Tarlatamab, a bispecific T-cell engager immunotherapy targeting delta-like ligand 3 and CD3, showed promising antitumor activity in a phase 1 trial in patients with previously treated small-cell lu ...